Viability of CLL Samples Exposed to Depsipeptide Expressed as Percentage of Viability Versus Control ± Standard Deviation
| Depsipeptide Concentration (μmol/L) . | 4-h Exposure Then Washed and Viability Assessed at 4 d . | 1-d Exposure Then Washed and Viability Assessed at 4 d . | 4-d Exposure and Then Viability Assessed at 4 d . |
|---|---|---|---|
| 0.0001 | 92.3 ± 10.2 | 95.21 ± 9.1 | 96.1 ± 12.8 |
| 0.00033 | 107.64 ± 14.2 | 71.7 ± 23.0 | 81.3 ± 22.5 |
| 0.001 | 99.6 ± 24 | 70.0 ± 21.1 | 60.4 ± 24.7 |
| 0.01 | 49.0 ± 27.7 | 49.3 ± 25.1 | 25.1 ± 22.5 |
| 0.1 | 21.6 ± 18.2 | 26.3 ± 11.1 | 16.1 ± 11.1 |
| 1 | 21.2 ± 16.6 | 22.8 ± 12.8 | 12.6 ± 9.2 |
| 3.3 | 21.4 ± 16.2 | 21.3 ± 12.8 | 8.1 ± 10.2 |
| 10 | 17.0 ± 11.9 | 16.47 ± 9.9 | 5.1 ± 4.8 |
| 33 | 7.6 ± 2.6 | 6.15 ± 7.4 | 4.1 ± 3.4 |
| Depsipeptide Concentration (μmol/L) . | 4-h Exposure Then Washed and Viability Assessed at 4 d . | 1-d Exposure Then Washed and Viability Assessed at 4 d . | 4-d Exposure and Then Viability Assessed at 4 d . |
|---|---|---|---|
| 0.0001 | 92.3 ± 10.2 | 95.21 ± 9.1 | 96.1 ± 12.8 |
| 0.00033 | 107.64 ± 14.2 | 71.7 ± 23.0 | 81.3 ± 22.5 |
| 0.001 | 99.6 ± 24 | 70.0 ± 21.1 | 60.4 ± 24.7 |
| 0.01 | 49.0 ± 27.7 | 49.3 ± 25.1 | 25.1 ± 22.5 |
| 0.1 | 21.6 ± 18.2 | 26.3 ± 11.1 | 16.1 ± 11.1 |
| 1 | 21.2 ± 16.6 | 22.8 ± 12.8 | 12.6 ± 9.2 |
| 3.3 | 21.4 ± 16.2 | 21.3 ± 12.8 | 8.1 ± 10.2 |
| 10 | 17.0 ± 11.9 | 16.47 ± 9.9 | 5.1 ± 4.8 |
| 33 | 7.6 ± 2.6 | 6.15 ± 7.4 | 4.1 ± 3.4 |